© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Marcia S. Brose, MD, PhD, discusses 2 patient cases of differentiated thyroid cancer (DTC) and explains the DTC treatment landscape.
March 11th 2022
Marcia S. Brose, MD, PhD, introduces our first patient case, a 70-year-old woman with differentiated thyroid cancer (DTC).
Dr Brose delves into radioiodine-refractory differentiated thyroid (RR-DTC), from its definition and the clinical molecular markers that impact that refractoriness.
Dr Brose reviews frontline treatment options for radioiodine-refractory differentiated thyroid cancer (RR-DTC).
An expert explains the impact of patient age when taking lenvatinib for treatment.
A medical professional discusses Study 211 data and HRQoL analyses for patients with DTC on lenvatinib.
Dr Brose elaborates on treating patients with DTC with lenvatinib, including starting dosage and toxicities/adverse events.
Marcia S. Brose, MD, PhD, introduces our second patient case, a 57-year-old man with DTC.
A medical professional explains how the size of lung metastases affect the treatment of DTC and clinician decision-making.
An expert briefly discusses the second-line treatment options for patients with DTC that have progressed on first-line therapy.
Marcia S. Brose, MD, PhD, concludes by listing some future directions she’d like to see within the treatment landscape, as well unmet needs that she hopes will be considered.